Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Centoxin

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Summary The challenges of sepsis, the inflammatory cascade and multi organ failure have remained central to the practice of… Expand
Is this relevant?
Review
2012
Review
2012
This paper examines the development and termination of nebacumab (Centoxin®), a human IgM monoclonal antibody (mAb) drug… Expand
Is this relevant?
2012
2012
SummaryMonoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative… Expand
  • table I
  • table II
Is this relevant?
Review
2000
Review
2000
Meningococcal septic shock (MSS) has high mortality and morbidity rates. In addition to the traditional prompt antibiotics and… Expand
Is this relevant?
1998
1998
ABSTRACT This note describes the binding specificities of four lipid A monoclonal antibodies (MAbs) including Centoxin (HA-1A… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1995
1995
Human IgM monoclonal antibody A6H4C5 was manufactured by Centocor (Malvern, PA) and used in clinical trials as HA-1A (Centoxin… Expand
Is this relevant?
1994
1994
  • Archives of internal medicine
  • 1994
  • Corpus ID: 23610306
BACKGROUND Antiendotoxin monoclonal antibodies are under investigation as adjunctive therapy for severe sepsis. One of these… Expand
Is this relevant?
1994
1994
The cytokines interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF alpha) have been… Expand
  • table I
  • figure 2
  • figure 1
  • figure 3
  • table 2
Is this relevant?
1994
1994
ObjectiveThe in vivo neutralizing activities of an anti-lipopolysaccharide (LPS) antibody HA-1A (Centoxin [Centocor, Malvern, PA… Expand
Is this relevant?
1993
1993
SiR,—Gram-negative septicaemia is an important cause of mortality in hospital patients, especially when accompanied by… Expand
Is this relevant?